- 1.
Rolin J, Ødegård RA, Amundsen VV et al. Medikamentell tilleggsbehandling for vektreduksjon hos ungdom med alvorlig fedme. Tidsskr Nor Legeforen 2022; 142. doi: 10.4045/tidsskr.22.0540. [PubMed][CrossRef]
- 2.
Kelly AS, Auerbach P, Barrientos-Perez M et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med 2020; 382: 2117–28. [PubMed][CrossRef]
- 3.
Helsedirektoratet. Folketrygdloven kapittel 5 med tilhørende bestemmelser. https://www.helsedirektoratet.no/rundskriv/kapittel-5-stonad-ved-helsetjenester/vedlegg-1-til--5-14-legemiddellisten/virkestoffer/liraglutid-2 Lest 31.1.2023.
- 4.
Rubino DM, Greenway FL, Khalid U et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA 2022; 327: 138–50. [PubMed][CrossRef]
- 5.
Statens legemiddelverk. Wegovy innvilges ikke blå resept. https://legemiddelverket.no/nyheter/wegovy-innvilges-ikke-bla-resept Lest 31.1.2023.
- 6.
Chen Z, Li S, Zeng L et al. Accessibility of Medicines for Children: A Systematic Review. Front Pharmacol 2021; 12: 691606. [PubMed][CrossRef]
- 7.
American Academy of Pediatrics. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. https://www.aap.org/en/patient-care/institute-for-healthy-childhood-weight/clinical-practice-guideline-for-the-evaluation-and-treatment-of-pediatric-obesity/ Lest 31.1.2023.
- 8.
Skodvin VA, Lekhal S, Kommedal KG et al. Livsstilsbehandling av barn og ungdom med alvorlig fedme – resultater etter ett år. Tidsskr Nor Legeforen 2020; 140. doi: 10.4045/tidsskr.19.0682. [PubMed][CrossRef]
- 9.
Benestad B, Lekhal S, Småstuen MC et al. Camp-based family treatment of childhood obesity: randomised controlled trial. Arch Dis Child 2017; 102: 303–10. [PubMed][CrossRef]
- 10.
National Institute for Health and Care Excellence. NICE recommends new treatment option for adults with obesity and non-diabetic hyperglycaemia who have a high risk of cardiovascular disease. https://www.nice.org.uk/news/article/nice-recommends-new-treatment-option-for-adults-with-obesity-and-non-diabetic-hyperglycaemia-who-have-a-high-risk-of-cardiovascular-disease Lest 31.1.2023.
- 11.
Brækhus LA. Slankemedisinen Wegovy innvilges ikke blå resept. Dagens Medisin 19.1.2023. https://www.dagensmedisin.no/fedme-legemiddelverket-legemidler/slankemedisinen-wegovy-innvilges-ikke-bla-resept/510609 Lest 31.1.2023.
()